Please login to the form below

Not currently logged in
Email:
Password:

Swiss biotech Inositec appoints new chief medical officer

Dr Frits van Alphen joins the group from Roche

Zurich-based biotechnology company Inositec has appointed a new chief medical officer in the form of Dr Frits van Alphen.

He said: “As CMO of Inositec, I have the golden opportunity to utilise my broad experience and entrepreneurial mind-set to develop new medicines.

“These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need.”

Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at Novartis as well as heading their clinical operations team in the Netherlands.

Dr Mattias Ivarsson, chief medical officer of Inositec, said: “Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with out lead programme in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019.”

23rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics